• Home
  • LOTTE Biologics

LOTTE Biologics

  • LOTTE BIOLOGICS
About LOTTE Biologics

LOTTE BIOLOGICS, is a premier global CDMO dedicated to providing top-quality biopharmaceuticals. We have pursued swift global expansion following the acquisition of BMS' Syracuse site, a location with over 62 international regulatory approvals and a 40,000L production capacity. Our capabilities span from cell line development to biologics drug substance manufacturing, with an ADC conjugation facility planned. Future expansion includes three Mega Plants in Korea with a projected capacity exceeding +360,000L by 2030 with the first plant expected to be GMP-ready by 4Q 2026. 

Read more Show less
Certifications
  • FDA
    FDA
  • GMP
    GMP
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • KR
  • 2022
    On CPHI since
  • 2
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024
View Exhibitor Profile

LOTTE Biologics Resources (1)

  • LOTTE BIOLOGICS Brochure

    Brochure LOTTE BIOLOGICS Brochure

    LOTTE BIOLOGICS is a premier global CDMO dedicated to providing top-quality biopharmaceuticals. We have pursued swift global expansion following the acquisition of BMS' Syracuse site, a location with over 62 international regulatory approvals and a 35,000L production capacity. Our capabilities span from cell line development to biologics drug substance manufacturing, with an ADC conjugation facility planned. Future expansion includes three Mega Plants in Korea with a projected capacity exceeding 360,000L, with the first plant expected to be GMP-ready by 2026 and the entire facility fully operational by 2030. Visit https://www.lottebiologics.com/en/